Under the deal, Sanofi will pay Kymab $1.1 billion in cash upfront and up to another $350 million based on certain milestones.
The transaction gives Sanofi global rights to KY1005, Kymab’s human monoclonal antibody that has shown promise in treating severe eczema during clinical trials.
“The Kymab acquisition adds KY1005 to our dynamic pipeline, a potential first-in-class treatment for a range of immune and inflammatory diseases,” Sanofi CEO Paul Hudson said in a news release. “We look forward to rapidly developing this investigational medicine.”
Sanofi will also gain rights to Kymab’s experimental monoclonal antibody cancer treatment, antibody technologies and research capabilities.
More articles on pharmacy:
What more pharmacy deserts amid the pandemic means for public health
Pfizer vaccine effective against UK, South Africa COVID-19 strains, study suggests
New York to launch COVID-19 vaccination phase 1b
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
